Kalaris Therapeutics (KLRS) Tax Provisions (2021 - 2023)
Kalaris Therapeutics (KLRS) posted quarterly Tax Provisions of -$40.0 million for Q4 2023, down 12.17% year-over-year from -$45.6 million in Q4 2022, and down 12.17% quarter-over-quarter from -$35.7 million in Q4 2022.
Kalaris Therapeutics (KLRS) Tax Provisions (2021 - 2023) Analysis & Trends
Kalaris Therapeutics' Tax Provisions history runs 3 years deep, the most recent figure standing at -$40.0 million for Q4 2023.
- In Q4 2023, Tax Provisions fell 12.17% year-over-year to -$40.0 million; the TTM figure through Dec 2023 stood at -$75.7 million (down 113.37% YoY), while the FY2024 annual figure was $3.0 million, up 107.4% from the prior year.
- Tax Provisions for Q4 2023 stood at -$40.0 million, down from -$35.7 million in the prior quarter.
- The five-year high for Tax Provisions was $1.0 million in Q4 2021, with the low at -$40.0 million in Q4 2023.
- The 3-year median for Tax Provisions is -$17.7 million (2022), against an average of -$18.6 million.
- The sharpest annual moves came in 2022 and 2023: Tax Provisions tumbled 3667.2% in 2022, then fell 12.17% in 2023.
- Kalaris Therapeutics' Tax Provisions stood at $1.0 million in 2021, then sank by 3667.2% to -$35.7 million in 2022, then fell by 12.17% to -$40.0 million in 2023.
- Business Quant data shows KLRS's Tax Provisions at -$40.0 million in Q4 2023, -$35.7 million in Q4 2022, and $200000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -40.02 Mn |
| Dec 31, 2022 | -35.67 Mn |
| Jun 30, 2022 | 200,000.00 |
| Dec 31, 2021 | 1.00 Mn |